117 related articles for article (PubMed ID: 34425470)
21. Type 17 immunity promotes the exhaustion of CD8
Kim BS; Kuen DS; Koh CH; Kim HD; Chang SH; Kim S; Jeon YK; Park YJ; Choi G; Kim J; Kang KW; Kim HY; Kang SJ; Hwang S; Shin EC; Kang CY; Dong C; Chung Y
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083422
[TBL] [Abstract][Full Text] [Related]
22. PD1
Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus.
Souabni A; Jochum W; Busslinger M
Blood; 2007 Jan; 109(1):281-9. PubMed ID: 16968900
[TBL] [Abstract][Full Text] [Related]
24. The activating protein 1 transcription factor basic leucine zipper transcription factor, ATF-like (BATF), regulates lymphocyte- and mast cell-driven immune responses in the setting of allergic asthma.
Übel C; Sopel N; Graser A; Hildner K; Reinhardt C; Zimmermann T; Rieker RJ; Maier A; Neurath MF; Murphy KM; Finotto S
J Allergy Clin Immunol; 2014 Jan; 133(1):198-206.e1-9. PubMed ID: 24290279
[TBL] [Abstract][Full Text] [Related]
25. PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.
Jamrog L; Chemin G; Fregona V; Coster L; Pasquet M; Oudinet C; Rouquié N; Prade N; Lagarde S; Cresson C; Hébrard S; Nguyen Huu NS; Bousquet M; Quelen C; Brousset P; Mancini SJC; Delabesse E; Khamlichi AA; Gerby B; Broccardo C
Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10357-10362. PubMed ID: 30257940
[No Abstract] [Full Text] [Related]
26. B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia.
Imoto N; Hayakawa F; Kurahashi S; Morishita T; Kojima Y; Yasuda T; Sugimoto K; Tsuzuki S; Naoe T; Kiyoi H
J Biol Chem; 2016 Feb; 291(9):4723-31. PubMed ID: 26703467
[TBL] [Abstract][Full Text] [Related]
27. CD8
Xu C; Lu X; Liu W; Chen A; Meng G; Zhang H; Li B; Zhang Y; Wu J; Wei J
J Transl Med; 2018 May; 16(1):132. PubMed ID: 29784005
[TBL] [Abstract][Full Text] [Related]
28. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
[TBL] [Abstract][Full Text] [Related]
29. Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker.
Nasr MR; Rosenthal N; Syrbu S
Am J Clin Pathol; 2010 Jan; 133(1):41-8. PubMed ID: 20023257
[TBL] [Abstract][Full Text] [Related]
30. CD8
Tao J; Han D; Gao S; Zhang W; Yu H; Liu P; Fu R; Li L; Shao Z
J Cell Mol Med; 2020 Jan; 24(1):1046-1058. PubMed ID: 31756785
[TBL] [Abstract][Full Text] [Related]
31. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
32. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.
Fu C; Jiang A
Front Immunol; 2018; 9():3059. PubMed ID: 30619378
[TBL] [Abstract][Full Text] [Related]
33. Activating PAX gene family paralogs to complement PAX5 leukemia driver mutations.
Hart MR; Anderson DJ; Porter CC; Neff T; Levin M; Horwitz MS
PLoS Genet; 2018 Sep; 14(9):e1007642. PubMed ID: 30216339
[TBL] [Abstract][Full Text] [Related]
34. Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase.
Vazquez-Cintron EJ; Monu NR; Frey AB
J Immunol; 2010 Dec; 185(12):7133-40. PubMed ID: 21127315
[TBL] [Abstract][Full Text] [Related]
35. Pax5: a master regulator of B cell development and leukemogenesis.
Medvedovic J; Ebert A; Tagoh H; Busslinger M
Adv Immunol; 2011; 111():179-206. PubMed ID: 21970955
[TBL] [Abstract][Full Text] [Related]
36. RUNX1 Mutations Can Lead to Aberrant Expression of CD79a and PAX5 in Acute Myelogenous Leukemias: A Potential Diagnostic Pitfall.
Menter T; Lundberg P; Wenzel F; Dirks J; Fernandez P; Friess D; Dirnhofer S; Tzankov A
Pathobiology; 2019; 86(2-3):162-166. PubMed ID: 30396184
[TBL] [Abstract][Full Text] [Related]
37. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
[TBL] [Abstract][Full Text] [Related]
38. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
39. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
Wang QM; Lian GY; Song Y; Huang YF; Gong Y
Life Sci; 2019 Aug; 231():116335. PubMed ID: 30898647
[TBL] [Abstract][Full Text] [Related]
40. PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia.
Tiacci E; Pileri S; Orleth A; Pacini R; Tabarrini A; Frenguelli F; Liso A; Diverio D; Lo-Coco F; Falini B
Cancer Res; 2004 Oct; 64(20):7399-404. PubMed ID: 15492262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
